Study of XBD173 for pulmonary arterial hypertension (PAH)
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an experimental drug called XBD173 to see if it can reduce blood vessel inflammation and lower pressure in the lungs of people with pulmonary arterial hypertension (PAH). If you have a PAH diagnosis, are on two or more PAH medications, and already have a heart and lung monitor implanted, this study may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of pulmonary arterial hypertension (PAH) – either idiopathic, heritable, related to connective tissue disease, or caused by certain drugs or a repaired heart defect.
- You are taking at least two PAH medications and have been on the same doses for at least one month.
- You already have a heart rhythm monitor and a pulmonary artery pressure monitor implanted.
- You are willing to have a genetic test to check for genes that might affect the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
Hear when a new Pulmonary Artery Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.